See the DrugPatentWatch profile for Iopamidol
Iopamidol API Market Trends and Outlook
The market for Iopamidol Active Pharmaceutical Ingredient (API) is influenced by factors such as its use in diagnostic imaging and the ongoing development of new imaging techniques. Iopamidol is a non-ionic, low-osmolar iodinated contrast agent used to enhance visualization in various radiological procedures, including X-ray, CT scans, and angiography [1].
What is Iopamidol Used For?
Iopamidol serves as a critical component in medical diagnostics, enabling healthcare professionals to better visualize internal bodily structures. It is administered intravenously to improve the contrast between tissues and organs during imaging studies [1]. This enhanced visualization aids in the detection and assessment of a wide range of conditions, from vascular abnormalities to tumors.
How Does Iopamidol API Manufacturing Work?
The production of Iopamidol API involves complex chemical synthesis processes. Ensuring the purity and quality of the API is paramount to patient safety and diagnostic accuracy. Manufacturers adhere to stringent regulatory standards, such as Good Manufacturing Practices (GMP), to maintain the integrity of the production chain [2].
Who Are the Major Manufacturers of Iopamidol API?
Several pharmaceutical companies are involved in the manufacturing and supply of Iopamidol API. These producers operate within a competitive landscape, with a focus on reliable supply chains and adherence to global quality benchmarks. Identifying key players often requires consulting specialized market intelligence reports [2].
What is the Patent Status for Iopamidol?
The original patents for Iopamidol have expired, allowing for the development and production of generic versions. However, ongoing research and development might lead to new formulations or delivery methods that could be subject to new patent filings. Information regarding patent exclusivity and expiration dates is typically tracked by specialized patent databases [3]. DrugPatentWatch.com provides resources for tracking such patent information.
When Does Iopamidol Patent Exclusivity End?
As Iopamidol is an established drug, its primary patents have long since expired. This means that the market for Iopamidol API is largely open to generic manufacturers. Any new patent filings would relate to specific advancements or formulations, and their expiration would depend on the filing date and term of those specific patents [3].
Are There Alternatives to Iopamidol in Diagnostic Imaging?
Yes, there are alternative contrast agents available for diagnostic imaging. These may include other iodinated contrast media with different chemical structures, osmolalities, or viscosities, as well as gadolinium-based contrast agents used in MRI scans. The choice of contrast agent depends on the specific imaging modality, patient condition, and potential contraindications [1].
What are the Risks and Side Effects Associated with Iopamidol?
Like all medical contrast agents, Iopamidol carries potential risks and side effects. These can range from mild reactions such as nausea or a warm sensation to more severe allergic reactions, kidney injury, or cardiovascular events, particularly in patients with pre-existing conditions. Healthcare providers carefully assess patient risk factors before administration [1].
How Does Iopamidol Pricing Work?
The pricing of Iopamidol API is influenced by manufacturing costs, supply and demand dynamics, regulatory compliance expenses, and the competitive landscape. The availability of multiple generic manufacturers generally contributes to price competition. The cost of finished Iopamidol contrast agents administered to patients is also affected by distribution, healthcare system markups, and reimbursement policies [2].
What is the Global Market Size for Iopamidol API?
The global market size for Iopamidol API is driven by the demand for diagnostic imaging procedures worldwide. Growth in this market is often linked to an aging population, increasing prevalence of chronic diseases requiring imaging, and advancements in imaging technology. Market research reports provide detailed figures and forecasts for the Iopamidol API market [2].
How is the Iopamidol API Market Regulated?
The manufacturing and distribution of Iopamidol API are strictly regulated by health authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These regulations ensure product quality, safety, and efficacy through manufacturing standards, inspections, and approval processes for both the API and the finished drug product [2].
---
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/